Equifax CEO Mark W. Begor sells 37,792 shares

The sales covered 37,792 shares and were made under a Rule 10b5-1 plan adopted on October 28, 2025.

Rhea-AI Filing Summary

Equifax Inc. CEO Mark W. Begor exercised options covering 37,792 shares of common stock on October 23, 2026, at an exercise price of $112.46 per share, then sold 37,792 shares that day in four transactions. The reported option position was zero after the exercise. The sales were made under a Rule 10b5-1 trading plan adopted October 28, 2025.

Reported sale prices were 1,194 shares at a weighted average of $186.7335 per share; 1,250 at $183.4030; 1,681 at a weighted average of $185.2034; and 33,667 at a weighted average of $182.5170. Separate indirect common-stock holdings were listed in five GRATs: 2,350 shares in the 2-yr Apr 2025 GRAT, 21,284 in the 2-yr Dec 2025 GRAT, 20,512 in the 2-yr Jun 2025 GRAT, 2,018 in the 2-yr May 2025 GRAT, and 18,562 in the 2-yr May 2026 GRAT.

Insider Trade Summary 10b5-1

Exercise and Sale: 37,792 shares ($2.66M approx. pre-tax spread)

Exercise and Sale 11 txns

Insider Begor Mark W

Role CEO

Sold 37,792 shs ($6.91M)

Approx. gross sale proceeds $6.91M

Approx. exercise cost $4.25M

Approx. pre-tax spread $2.66M

Type	Security	Shares	Price	Value
Exercise	Stock Option/Right to Buy F1, F6	37,792	$0.00	$0.00
Exercise	Common Stock F1, F2	37,792	$112.46	$4.25M
Sale	Common Stock F1, F3, F2	1,194	$186.7335	$223K
Sale	Common Stock F1, F2	1,250	$183.403	$229K
Sale	Common Stock F1, F4, F2	1,681	$185.2034	$311K
Sale	Common Stock F1, F5, F2	33,667	$182.517	$6.14M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option/Right to Buy — 0 contracts (Direct); Common Stock — 289,922 shares (Direct); Common Stock — 2,350 shares (Indirect, 2-yr Apr 2025 GRAT); Common Stock — 21,284 shares (Indirect, 2-yr Dec 2025 GRAT); Common Stock — 20,512 shares (Indirect, 2-yr Jun 2025 GRAT); Common Stock — 2,018 shares (Indirect, 2-yr May 2025 GRAT); Common Stock — 18,562 shares (Indirect, 2-yr May 2026 GRAT)

Footnotes (6)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.
2. F2. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.
3. F3. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
4. F4. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
5. F5. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
6. F6. The option vested in three equal annual increments beginning 5/4/2019.

Key Figures

Options exercised: 37,792 shares; $112.46 exercise price per share Shares sold: 37,792 shares First sale: 1,194 shares; $186.7335 weighted average per share +3 more

6 metrics

Options exercised 37,792 shares; $112.46 exercise price per share October 23, 2026

Shares sold 37,792 shares October 23, 2026

First sale 1,194 shares; $186.7335 weighted average per share October 23, 2026

Second sale 1,250 shares; $183.4030 per share October 23, 2026

Third sale 1,681 shares; $185.2034 weighted average per share October 23, 2026

Fourth sale 33,667 shares; $182.5170 weighted average per share October 23, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, GRAT, dividend equivalent units

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

GRAT financial

"2-yr Apr 2025 GRAT"

dividend equivalent units financial

"Includes accrued dividend equivalent units"

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EFX shares did CEO Mark W. Begor sell, and at what prices?

Mark W. Begor sold 37,792 shares on October 23, 2026, in four transactions: 1,194 shares at a weighted average of $186.7335 per share; 1,250 at $183.4030; 1,681 at a weighted average of $185.2034; and 33,667 at a weighted average of $182.5170. The sales were made under a Rule 10b5-1 trading plan adopted October 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:17 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Begor Mark W

(Last) (First) (Middle)

1550 PEACHTREE STREET, N.W.

(Street)

ATLANTA GEORGIA 30309

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EQUIFAX INC [ EFX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/23/2026		M(1)		37,792	A	$112.46	327,714(2)	D
Common Stock	10/23/2026		S(1)		1,194	D	$186.7335(3)	326,520(2)	D
Common Stock	10/23/2026		S(1)		1,250	D	$183.403	325,270(2)	D
Common Stock	10/23/2026		S(1)		1,681	D	$185.2034(4)	323,589(2)	D
Common Stock	10/23/2026		S(1)		33,667	D	$182.517(5)	289,922(2)	D
Common Stock								2,350	I	2-yr Apr 2025 GRAT
Common Stock								21,284	I	2-yr Dec 2025 GRAT
Common Stock								20,512	I	2-yr Jun 2025 GRAT
Common Stock								2,018	I	2-yr May 2025 GRAT
Common Stock								18,562	I	2-yr May 2026 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option/Right to Buy	$112.46	10/23/2026		M(1)			37,792	(6)	05/04/2028	Common Stock	37,792	$0.0000	0.0000	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

2. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

3. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

4. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

5. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

6. The option vested in three equal annual increments beginning 5/4/2019.

	/s/Lisa Stockard as Attorney-in-Fact	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)